Venture capital firm Frazier Healthcare Partners announced the promotion of several members on its Life Sciences team.
These are Aditya Kohli to Venture Partner, Anna Chen to Vice President, and Max Nowicki to Senior Associate.
Aditya Kohli, Ph.D., joined the Frazier Life Sciences team in 2016 and focuses on company creation. He co-founded Phathom Pharmaceuticals (NASDAQ: PHAT) and Scout Bio, and helped launch Passage Bio (NASDAQ: PASG). Dr. Kohli serves as the Chief Business Officer of Phathom Pharmaceuticals and as a member of the board of directors for Scout Bio.
Anna Chen, Ph.D., joined Frazier in 2018 and focuses on evaluating investment opportunities and creating new ventures in the life sciences sector. She is a board observer for Amunix Pharmaceuticals and Inipharm.
Max Nowicki, M.D., joined the Frazier Life Sciences team in 2019 and focuses on identifying new public and private investment opportunities. He has been involved in numerous Frazier investments, including Rocket Pharmaceuticals (NASDAQ: RCKT) and Trillium Therapeutics (NASDAQ: TRIL).
Founded in 1991, Frazier Healthcare Partners is a provider of growth and venture capital to healthcare companies. With nearly $4.8 billion total capital raised, the firm has invested in over 200 companies, with investment types ranging from company creation and venture capital to buyouts of profitable lower-middle market companies. The firm’s Growth Buyout team invests in healthcare and pharmaceutical services, medical products and related sectors. The Life Sciences team invests in therapeutics and related areas that are addressing unmet medical needs through innovation.
Frazier has offices in Seattle, WA and Menlo Park, CA, and invests broadly across the US, Canada, and Europe.
FinSMEs
07/01/2020